MM&M

Sanofi, Maze strike $150M licensing deal for glycogen synthase 1 program

Sanofi has sealed a $150 million licensing deal to gain access to Maze’s glycogen synthase 1 (GYS1) program, landing the company’s lead candidate MZE001 in the process. The licensing agreement ...
Business Wire

Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new data from an exploratory muscle biopsy cohort ...
Monthly Prescribing Reference

Oral Glycogen Synthase Inhibitor Designated Orphan Drug for Pompe Disease

Credit: Getty Images. Pompe disease is a rare, degenerative muscle disorder caused by mutations in the acid alpha-glucosidase gene, which leads to the abnormal buildup of glycogen. The Food and Drug ...
Business Wire

Maze Therapeutics Announces FDA Orphan Drug Designation Granted to MZE001 for the Treatment of Pompe Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the U.S. Food and Drug Administration (FDA) ...
Benzinga.com

Sanofi In-Licenses Pompe Disease Therapy From Privately-Held Maze Therapeutics For $150M Upfront

Maze Therapeutics has signed an exclusive worldwide license agreement with Sanofi SA SNY for Maze's glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is currently in ...
Pharmabiz

Researchers solve 3-D atomic structure of glycogen synthase kinase 3 beta enzyme

Researchers from Vertex Pharmaceuticals Incorporated have solved the three-dimensional atomic structure of glycogen synthase kinase 3 beta (GSK3), an enzyme involved in the regulation of blood glucose ...